 NEWTOWN, Pa., March 23, 2022 GLOBE NEWSWIRE -- Onconova Therapeutics, Inc. NASDAQ: ONTX, a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Adar Makovski Silverstein, Ph.D., Director of Corporate Development for Onconova, will present a high-level overview of the Companys narazaciclib program at the Next Generation Kinase Inhibitors Summit on March 30, 2022, at 2:00 p.m. ET. 